White Papers
- Article: “Factors Influencing The Reimbursement Of Novel Oral Oncology Therapies: A Perspective Of The Dynamic Reimbursement Landscape”
Marketing and sales of oncology agents has evolved as the FDA approved almost 20 new molecular entities
(NMEs) in 2007 alone, of which 20% include oral oncology agents. As with all innovative products, these oral
cancer agents carry high costs, ranging from $10,000 to $50,000 per patient per year. Despite high costs, the
value of oral oncology agents continues to be recognized by the clinical community. However, with increases
in the prevalence of cancer and the number of novel (i.e., new and targeted) oral oncology agents competing
to treat patients, these costly products are setting the stage for increased scrutiny in reimbursement.
In this paper, we review the environmental factors impacting the reimbursement of novel oral oncology
agents with a snapshot into the future, and provide key insights for manufacturers of oral oncologics.
Request Article